Greenleaf Trust purchased a new stake in Grifols, S.A. (NASDAQ:GRFS – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 41,384 shares of the biotechnology company’s stock, valued at approximately $352,000.
Other hedge funds have also recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new stake in shares of Grifols during the fourth quarter valued at approximately $5,694,000. Cardinal Capital Management raised its stake in shares of Grifols by 49.6% during the fourth quarter. Cardinal Capital Management now owns 71,405 shares of the biotechnology company’s stock valued at $607,000 after purchasing an additional 23,675 shares during the period. Sequoia Financial Advisors LLC purchased a new stake in shares of Grifols during the fourth quarter valued at approximately $185,000. Ronald Blue Trust Inc. bought a new stake in shares of Grifols in the fourth quarter worth $38,000. Finally, Hennion & Walsh Asset Management Inc. increased its stake in shares of Grifols by 184.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 150,306 shares of the biotechnology company’s stock worth $1,278,000 after buying an additional 97,469 shares during the last quarter. Hedge funds and other institutional investors own 14.41% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the stock. Morgan Stanley lowered shares of Grifols from an “overweight” rating to an “equal weight” rating in a research note on Friday, March 3rd. AlphaValue raised shares of Grifols to a “buy” rating in a report on Monday, February 6th. StockNews.com raised shares of Grifols from a “hold” rating to a “buy” rating in a report on Wednesday, March 29th. Jefferies Financial Group raised shares of Grifols from a “hold” rating to a “buy” rating in a report on Wednesday, January 18th. Finally, Barclays raised shares of Grifols from an “underweight” rating to an “equal weight” rating in a report on Thursday, February 16th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.52.
Grifols Trading Up 5.2 %
About Grifols
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy.
Recommended Stories
- Get a free copy of the StockNews.com research report on Grifols (GRFS)
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
- FedEx Takes Flight; Analysts See More Gains Ahead
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.
